Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/WNO.0000000000002155 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case series on 2 cases of macular damage caused by the novel coronavirus: A case report.
Medicine (Baltimore)
January 2025
Xi'an BRIGHT Eye Hospital Group Co Ltd. Xi'an, Shaanxi, China.
Rationale: Macular damage is a rare yet significant ocular complication of coronavirus disease 2019 (COVID-19) infection. This report highlights the clinical features, diagnosis, treatment, and outcomes in 2 cases of COVID-19-associated macular damage, contributing to the understanding of its pathophysiology and management.
Patient Concerns: Both patients presented with a sudden onset of visual impairment and black shadows in their central visual fields shortly after contracting COVID-19.
Clinical predictors in acute optic neuritis: Analysis based on clinical trial data.
Ophthalmology
January 2025
Eye Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany.
Purpose: To identify baseline clinical predictors of visual outcomes six months after acute optic neuritis using data from our completed clinical neuroprotection trial (TONE study).
Design: Secondary analysis of data from the TONE study cohort (NCT01962571).
Subjects: Total of 103 patients presenting within 10 days of a first episode of acute unilateral optic neuritis as a clinically isolated syndrome with baseline high contrast visual acuity (HCVA) < 20/40 Snellen (logMAR 0.
Transient anterior chamber intraocular lens opacification by triamcinolone acetonide following intravitreal injection.
GMS Ophthalmol Cases
December 2024
Department of Ophthalmology, Disha Eye Hospital, Siliguri, India.
Background: Pseudophakic cystoid macular edema (CME) following primary anterior-chamber intraocular lens (ACIOL) implantations is commonly seen. Intravitreal triamcinolone acetonide (IVTA) injections have shown significant improvement in visual acuity and retinal thickness in refractory pseudophakic CME. Pseudohypopyon following IVTA injection is a known entity.
View Article and Find Full Text PDFAcute macular neuroretinopathy occurrence in a Behçet disease patient: a case report.
J Ophthalmic Inflamm Infect
January 2025
Ophthalmology Department, CHIREC Braine-l'Alleud-Waterloo Hospital, Braine l'Alleud, Belgium.
Purpose: To report the occurrence of AMN (Acute Macular Neuroretinopathy) in a Behçet Disease (BD) patient during an active systemic inflammatory relapse and to describe the SD-OCT features of this entity.
Patients And Methods: Retrospective observational case report of a patient who presented with an AMN during a BD associated ocular inflammation (Saint Pierre Hospital, Brussels, Belgium). Clinical record and imaging, including infrared reflectance image (IR) and spectral domain optical coherence tomography (SD-OCT), were analyzed.
Safety and Efficacy of Long-term Use of Infliximab in Severe Juvenile Dermatomyositis - 12 Years of Follow-up.
Acta Dermatovenerol Croat
November 2024
Prof. Marija Jelušić, MD, PhD, Department of Paediatrics, University of Zagreb, School of Medicine, Division of Clinical Immunology, Rheumatology and Allergology, Centre of Reference for Paediatric and Adolescent Rheumatology of Ministry of Health of the Republic Croatia, University Hospital Centre Zagreb, Kispaticeva 12, 10 000 Zagreb, Croatia;
Juvenile dermatomyositis with emphasized vasculopathy is rare, but the most severe form of the disease, with a poor prognosis with relapsing and chronic course or, in some cases, lethal outcome. We present a case of a 19-year-old Caucasian female, who developed severe acute juvenile dermatomyositis with emphasized multisystem vasculopathy, including retinal vasculopathy and maculopathy (cotton-wool spots, retinal hemorrhages, macular edema) at the age of 8. Due to no response to standard treatment protocols and rapid worsening of clinical symptoms and laboratory findings, a TNF inhibitor (infliximab) was introduced after the third week of treatment resulting in complete normalisation of muscle enzyme levels and complete resolution of eye changes within the next 2 weeks with a gradual general recovery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!